journal
MENU ▼
Read by QxMD icon Read
search

Pituitary

journal
https://www.readbyqxmd.com/read/28224405/complications-of-acromegaly-cardiovascular-respiratory-and-metabolic-comorbidities
#1
REVIEW
Rosario Pivonello, Renata S Auriemma, Ludovica F S Grasso, Claudia Pivonello, Chiara Simeoli, Roberta Patalano, Mariano Galdiero, Annamaria Colao
Acromegaly is associated with an enhanced mortality, with cardiovascular and respiratory complications representing not only the most frequent comorbidities but also two of the main causes of deaths, whereas a minor role is played by metabolic complications, and particularly diabetes mellitus. The most prevalent cardiovascular complications of acromegaly include a cardiomyopathy, characterized by cardiac hypertrophy and diastolic and systolic dysfunction together with arterial hypertension, cardiac rhythm disorders and valve diseases, as well as vascular endothelial dysfunction...
February 21, 2017: Pituitary
https://www.readbyqxmd.com/read/28220351/two-dimensional-speckle-tracking-echocardiography-demonstrates-no-effect-of-active-acromegaly-on-left-ventricular-strain
#2
I C M Volschan, L Kasuki, C M S Silva, M L Alcantara, R M Saraiva, S S Xavier, M R Gadelha
BACKGROUND: Speckle tracking echocardiography (STE) allows for the study of myocardial strain (ε), a marker of early and subclinical ventricular systolic dysfunction. Cardiac disease may be present in patients with acromegaly; however, STE has never been used to evaluate these patients. OBJECTIVE: To evaluate left ventricular (LV) global longitudinal strain in patients with active acromegaly with normal LV systolic function. DESIGN: Cross-sectional clinical study...
February 20, 2017: Pituitary
https://www.readbyqxmd.com/read/28210909/the-longest-stalk-preserved-pituitary-function-after-regression-of-a-giant-prolactinoma
#3
LETTER
Jessica A Lundgren, Edward H Oldfield, John C Marshall
No abstract text is available yet for this article.
February 16, 2017: Pituitary
https://www.readbyqxmd.com/read/28210908/updates-in-outcomes-of-stereotactic-radiation-therapy-in-acromegaly
#4
REVIEW
Monica Livia Gheorghiu
Purpose Treatment of acromegaly has undergone important progress in the last 20 years mainly due to the development of new medical options and advances in surgical techniques. Pituitary surgery is usually first-line therapy, and medical treatment is indicated for persistent disease, while radiation (RT) is often used as third-line therapy. The benefits of RT (tumor volume control and decreased hormonal secretion) are hampered by the long latency of the effect and the high risk of adverse effects. Stereotactic RT methods have been developed with the aim to provide more precise targeting of the tumor with better control of the radiation dose received by the adjacent brain structures...
February 16, 2017: Pituitary
https://www.readbyqxmd.com/read/28197813/t2-weighted-mri-signal-intensity-as-a-predictor-of-hormonal-and-tumoral-responses-to-somatostatin-receptor-ligands-in-acromegaly-a-perspective
#5
REVIEW
Iulia Potorac, Albert Beckers, Jean-François Bonneville
T2-weighted MRI signal intensity of GH-secreting pituitary adenomas is gaining recognition as a marker of disease characteristics and may be a predictor of response to treatment of acromegaly. Adenomas that are T2-hypointense are more common, are smaller and are less likely to invade the cavernous sinus compared to the T2-iso and hyperintense tumors. T2-hypointense tumors are also accompanied by higher IGF1 values at baseline. When presurgical somatostatin receptor ligand (SRL) therapy is administered, T2-hypointense adenomas have better hormonal responses and have greater tumor shrinkage...
February 14, 2017: Pituitary
https://www.readbyqxmd.com/read/28176162/somatostatin-receptor-ligands-in-the-treatment-of-acromegaly
#6
REVIEW
Monica R Gadelha, Luiz Eduardo Wildemberg, Marcello D Bronstein, Federico Gatto, Diego Ferone
First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies. Many factors are involved in the resistance to SRL. In this review, we update the physiology of somatostatin and its receptors (sst), the use of SRL in the treatment of acromegaly and the factors involved in the response to these drugs. The SRL act through interaction with the sst, which up to now have been characterized as five subtypes...
February 7, 2017: Pituitary
https://www.readbyqxmd.com/read/28168377/biochemical-investigations-in-diagnosis-and-follow-up-of-acromegaly
#7
REVIEW
Katharina Schilbach, Christian J Strasburger, Martin Bidlingmaier
Measurements of human growth hormone (GH) and insulin-like growth-factor I (IGF-I) are cornerstones in the diagnosis of acromegaly. Both hormones are also used as biochemical markers in the evaluation of disease activity during treatment. Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I. While in some patients biological factors can explain the discrepancy, in many cases issues with the analytical methods seem to be responsible...
February 6, 2017: Pituitary
https://www.readbyqxmd.com/read/28161730/the-genetic-background-of-acromegaly
#8
REVIEW
Mônica R Gadelha, Leandro Kasuki, Márta Korbonits
Acromegaly is caused by a somatotropinoma in the vast majority of the cases. These are monoclonal tumors that can occur sporadically or rarely in a familial setting. In the last few years, novel familial syndromes have been described and recent studies explored the landscape of somatic mutations in sporadic somatotropinomas. This short review concentrates on the current knowledge of the genetic basis of both familial and sporadic acromegaly.
February 4, 2017: Pituitary
https://www.readbyqxmd.com/read/28154960/radiological-features-for-the-approach-in-trans-sphenoidal-pituitary-surgery
#9
Victoria Twigg, Simon D Carr, Ramkishan Balakumar, Saurabh Sinha, Showkat Mirza
INTRODUCTION: In order to perform trans-sphenoidal endoscopic pituitary surgery safely and efficiently it is important to identify anatomical and pituitary disease features on the pre-operative CT and MRI scans; thereby minimising the risk to surrounding structures and optimising outcomes. We aim to create a checklist to streamline pre-operative planning. METHODS: We retrospectively reviewed pre-operative CT and MRI scans of 100 adults undergoing trans-sphenoidal endoscopic pituitary surgery...
February 2, 2017: Pituitary
https://www.readbyqxmd.com/read/28091880/inhibition-of-neuronal-nitric-oxide-synthase-activity-does-not-alter-vasopressin-secretion-in-septic-rats
#10
Camila Henriques Coelho, Thalita Freitas Martins, Gabriela Ravanelli Oliveira-Pelegrin, Maria José Alves da Rocha
BACKGROUND/PURPOSE: During the early phase of sepsis, hypotension is accompanied by increase of plasma vasopressin hormone (AVP) levels, which decline during the late phase. This hypotension is due in part to increase of nitric oxide (NO) synthesis by nitric oxide synthase (NOS) enzyme. Neuronal isoform of this enzyme (nNOS) is present in vasopressinergics neurons of hypothalamus, but its role in vasopressin secretion during sepsis is unknown. METHODS: We evaluated the role of nNOS in NO production and vasopressin secretion during sepsis...
January 16, 2017: Pituitary
https://www.readbyqxmd.com/read/28091879/new-medical-therapies-on-the-horizon-oral-octreotide
#11
REVIEW
Nienke R Biermasz
Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly...
January 16, 2017: Pituitary
https://www.readbyqxmd.com/read/28074401/adipsic-diabetes-insipidus-in-adult-patients
#12
REVIEW
Martín Cuesta, Mark J Hannon, Christopher J Thompson
INTRODUCTION: Adipsic diabetes insipidus (ADI) is a very rare disorder, characterized by hypotonic polyuria due to arginine vasopressin (AVP) deficiency and failure to generate the sensation of thirst in response to hypernatraemia. As the sensation of thirst is the key homeostatic mechanism that prevents hypernatraemic dehydration in patients with untreated diabetes insipidus (DI), adipsia leads to failure to respond to aquaresis with appropriate fluid intake. This predisposes to the development of significant hypernatraemia, which is the typical biochemical manifestation of adipsic DI...
January 10, 2017: Pituitary
https://www.readbyqxmd.com/read/28025719/cabergoline-in-acromegaly
#13
REVIEW
Emmanuelle Kuhn, Philippe Chanson
Acromegaly, a rare disease due to growth hormone (GH) hypersecretion by a pituitary adenoma, is associated with severe comorbidity and premature death if not adequately treated. The usual first-line treatment is surgery. Various drugs, including somatostatin receptor ligands, dopamine agonists and GH receptor antagonists, are now available for use if surgery fails to suppress GH/IGF-I hypersecretion. Cabergoline, now the preferred dopamine agonist for treating hyperprolactinemia, is also used off-label for treating acromegaly...
December 26, 2016: Pituitary
https://www.readbyqxmd.com/read/27987061/management-of-aggressive-growth-hormone-secreting-pituitary-adenomas
#14
REVIEW
Daniel A Donoho, Namrata Bose, Gabriel Zada, John D Carmichael
Aggressive GH-secreting pituitary adenomas (GHPAs) represent an important clinical problem in patients with acromegaly. Surgical therapy, although often the mainstay of treatment for GHPAs, is less effective in aggressive GHPAs due to their invasive and destructive growth patterns, and their proclivity for infrasellar invasion. Medical therapies for GHPAs, including somatostatin analogues and GH receptor antagonists, are becoming increasingly important adjuncts to surgical intervention. Stereotactic radiosurgery serves as an important fallback therapy for tumors that cannot be cured with surgery and medications...
December 16, 2016: Pituitary
https://www.readbyqxmd.com/read/27900635/somatostatin-and-dopamine-receptor-regulation-of-pituitary-somatotroph-adenomas
#15
REVIEW
Anat Ben-Shlomo, Ning-Ai Liu, Shlomo Melmed
Somatostatin and dopamine receptors are expressed in normal and tumoral somatotroph cells. Upon receptor stimulation, somatostatin and the somatostatin receptor ligands octreotide, lanreotide, and pasireotide, and to a lesser extent, dopamine and the dopamine analogs bromocriptine and cabergoline, suppress growth hormone (GH) secretion from a GH-secreting pituitary somatotroph adenoma. Somatostatin and dopamine receptors are Gαi-protein coupled that inhibit adenylate cyclase activity and cAMP production and reduce intracellular calcium concentration and calcium flux oscillations...
November 29, 2016: Pituitary
https://www.readbyqxmd.com/read/27900634/socs2-polymorphisms-are-not-associated-with-clinical-and-biochemical-phenotypes-in-acromegalic-patients
#16
Ericka B Trarbach, Alexander A Jorge, Felipe H Duarte, Marcello D Bronstein, Raquel S Jallad
PURPOSE: Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly. METHODS: Four SOCS2 SNPs (rs3782415, rs3816997, rs3825199 and rs11107116) were selected and genotyped by real-time PCR using specific Taqman probe assays...
November 29, 2016: Pituitary
https://www.readbyqxmd.com/read/27743173/acknowledgement-of-reviewers-2015
#17
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Pituitary
https://www.readbyqxmd.com/read/27678103/long-term-outcomes-of-children-treated-for-cushing-s-disease-a-single-center-experience
#18
Galina Yordanova, Lee Martin, Farhad Afshar, Ian Sabin, Ghassan Alusi, Nicholas P Plowman, Fiona Riddoch, Jane Evanson, Matthew Matson, Ashley B Grossman, Scott A Akker, John P Monson, William M Drake, Martin O Savage, Helen L Storr
PURPOSE: Pediatric Cushing's disease (CD) is rare and there are limited data on the long-term outcomes. We assessed CD recurrence, body composition, pituitary function and psychiatric comorbidity in a cohort of pediatric CD patients. METHODS: Retrospective review of 21 CD patients, mean age at diagnosis 12.1 years (5.7-17.8), managed in our center between 1986 and 2010. Mean follow-up from definitive treatment was 10.6 years (2.9-27.2). RESULTS: Fifteen patients were in remission following transsphenoidal surgery (TSS) and 5 were in remission following TSS + external pituitary radiotherapy (RT)...
December 2016: Pituitary
https://www.readbyqxmd.com/read/27639583/paradoxical-and-atypical-responses-to-pasireotide-in-aggressive-acth-secreting-pituitary-tumors
#19
Yona Greenman, Naftali Stern
PURPOSE: Pasireotide is the only pituitary targeted medication registered for the treatment of Cushing's disease. Drug efficacy data are largely based on a major prospective study in which the vast majority of patients had microadenomas. The purpose of this study was to summarize results of pasireotide treatment of ACTH secreting macroadenomas from our center. METHODS: Retrospective review of data extracted from clinical files. RESULTS: Three patients presented with large and invasive macroadenomas that required several surgical interventions and radiotherapy treatments...
December 2016: Pituitary
https://www.readbyqxmd.com/read/27631333/childhood-acromegaly-due-to-x-linked-acrogigantism-long-term-follow-up
#20
Rebecca J Gordon, Jennifer Bell, Wendy K Chung, Raphael David, Sharon E Oberfield, Sharon L Wardlaw
PURPOSE: Acromegaly in infancy is extremely rare. We describe a 32 year old woman who presented at 6 months of age with isolated macrocephaly, followed by accelerated linear growth. At 21 months of age, her head circumference was 55 cm (+5.5 SD), height was 97.6 cm (+4.4 SD) and weight was 20.6 kg (+6.2 SD). She had markedly elevated levels of growth hormone (GH) (135 ng/ml), IGF-1 (1540 ng/ml) and prolactin (370 ng/ml). A pituitary macroadenoma was surgically resected. Immunohistochemical staining was positive for GH...
December 2016: Pituitary
journal
journal
33080
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"